

Fig. 4. Amplitudes and frequencies of mEPSCs in  $I_h$ -negative cells. One hundred twenty miniature events were pooled and analyzed for each  $I_h$ -negative cell. (A) The mean amplitude and frequency of mEPSCs were calculated in each cell and plotted (control:  $n=9$  cells from six animals; EGF:  $n=9$  cells from seven animals).  $t$ -test detected no significant differences. (B) Averaged cumulative histograms of inter-event intervals and amplitudes of mEPSCs were calculated and plotted with the same synaptic events for EGF-treated group and for saline-treated controls. \*  $P<0.05$ , K-S test.

2001; Yung, 1998). In contrast, the GluR4 AMPA receptor subunit is mainly expressed in neighboring GABAergic neurons (Paquet et al., 1997).

To examine the possibility that EGF administration influenced the expression of these glutamate receptor subunits, we determined the protein levels of AMPA and NMDA receptor subunits. Tissue containing the whole VTA and medial SNc was dissected from horizontal slices under a stereomicroscope and subjected to immunoblotting. We observed a statistically significant increase in the levels of the GluR1 subunit in animals receiving EGF ( $P=0.015$ ,  $t$ -test) (Fig. 6). GluR2/3 protein displayed a trend toward greater levels in EGF-treated animals, but did not reach statistical significance ( $P=0.067$ ). In contrast, GluR4 levels were not affected ( $P=0.35$ ). Protein levels of the NR1 NMDA receptor subunit were significantly elevated ( $P=0.030$ ), whereas NR2A and NR2B levels were not affected (NR2A,  $P=0.35$ ; NR2B,  $P=0.52$ ). In addition to the postsynaptic receptors, we examined the presynaptic markers synapsin I and synaptophysin. EGF administration had no effects on protein levels of these presynaptic molecules as well as a neuronal marker, NSE and an astrocyte marker, GFAP. These results suggest that synaptic potentiation following EGF administration might result from an increase in AMPA receptor expression in dopaminergic neurons.

## DISCUSSION

In the present study, we investigated subchronic influences of peripherally administered EGF on electrophysiological property of midbrain dopaminergic neurons in postnatal mice. Repeated administration of EGF enhanced excitatory synaptic transmission onto  $I_h$ -positive dopaminergic neurons in the VTA. Increases in the amplitude of mEPSCs and the AMPA/NMDA ratio were consistent with an increase in CNQX-sensitive potentials observed in field recording. In addition, we observed an elevation in the protein expression of the AMPA receptor subunit GluR1 and the NMDA receptor subunit NR1 in the ventral midbrain region. The elevation of glutamate receptor expression may underlie the increase in strength of synaptic inputs onto  $I_h$ -positive dopaminergic neurons.

In general, neurotrophic polypeptides exhibit distinct activities in acute and chronic phases (Patterson and Nawa, 1993). The acute effects mainly depend on intracellular signaling while chronic effects involve gene expression. Previous studies on hippocampal synaptic plasticity report the rapid synaptic responses to EGF. Acute application of EGF facilitates the induction of long term potentiation or enhances its magnitude (Ishiyama et al., 1991; Abe et al., 1991; Abe and Saito, 1992). Our preliminary study, however, indicated that acute EGF application to midbrain slice preparations failed to affect mEPSC (data not shown). Thus, the observed biological activity of EGF




Fig. 5. Effects of EGF on the AMPA/NMDA ratio of EPSCs evoked in putative dopaminergic neurons. (A) Averaged traces for 10 synaptic responses are shown. Synaptic responses were triggered by electrical stimulation (0.05–0.2 mA, 0.067 Hz). AMPA currents were recorded at a holding potential of  $-66$  mV. NMDA currents were recorded at a holding potential of  $34$  mV in the presence of  $10 \mu\text{M}$  CNQX. (B) The AMPA/NMDA ratio was calculated for each cell and plotted as the means  $\pm$  S.E.M (control:  $n=7$  cells from five animals; EGF,  $n=8$  cells from six animals). \*  $P<0.05$ ,  $t$ -test. (C) Typical responses of paired pulse inhibition of evoked EPSCs are shown for display. Four superimposed traces at the interval of  $20$  ms were recorded from control  $I_h$ -positive cells. Paired pulse ratios (peak amplitude of EPSC2/peak amplitude of EPSC1) were calculated from four averaged responses. (D) Paired pulse ratios at each stimulus interval ( $20$ ,  $50$ ,  $100$  ms) are calculated and plotted as the means  $\pm$  S.E.M (control:  $n=7$  cells from five animals; EGF,  $n=7$  cells from four animals).


presumably represents the slow neurotrophic action of EGF that regulates dopaminergic development.

In our experimental paradigm, dopaminergic neurons were identified by their electrophysiological property of the  $I_h$  currents. The recorded cells were localized in the anterior region of VTA in the horizontal slices (Ford et al., 2006). Accumulated evidence suggests that, in this brain region,  $I_h$  currents serve as a specific electrophysiological marker for dopaminergic neurons as identified with tyrosine hydroxylase immunoreactivity (Ford et al., 2006; Neuhoff et al., 2002; Johnson and North, 1992; Wanat et al., 2008; but see also Margolis et al., 2006). In agreement, we also found that more than 70% of  $I_h$ -positive cells showed tyrosine hydroxylase immunoreactivity in post-fixed slice preparations (data not shown). Although we cannot fully rule out the possibility that some of the  $I_h$ -positive cells, in parts, represented non-dopaminergic cells (Margolis et al., 2006), it is likely that the  $I_h$ -positive cells not carrying tyrosine hydroxylase immunoreactivity were produced by cell dialysis of a patch pipette during recording. Thus, we considered that the electrophysiological property of  $I_h$ -pos-

itive cells mainly represents that of dopaminergic neurons in the VTA.

Whole cell recording revealed cell specificity of the postsynaptic action of EGF. Synaptic facilitation triggered by EGF was limited to the dopaminergic neurons exhibiting prominent  $I_h$  currents. No significant differences were detected in either the amplitude or frequency of mEPSCs in the  $I_h$ -negative neurons. In this context, immunoblotting might support the specificity of the neurotrophic effects of EGF on dopaminergic neurons. In the midbrain, mRNA and protein for GluR1, GluR2/3 and NR1 are detectable in tyrosine hydroxylase-positive dopaminergic neurons, whereas GluR4 is expressed only in GABAergic neurons (Paquet et al., 1997; Chen et al., 2001; Yung, 1998). The evidence that GluR4 levels were not affected in mice receiving subchronic administration of EGF may suggest insensitivity of the GABAergic population to EGF. In contrast, an influence of EGF stimulation on afferent fibers to midbrain dopaminergic neurons was relatively limited. Subchronic EGF administration did not influence mEPSC frequency or the paired pulse ratio in putative dopaminergic neurons. Furthermore,





**Fig. 6.** Protein expression of glutamate receptor subunits in the VTA. After daily injection of saline or EGF, brain tissue around the VTA including SNc was dissected at P15 as shown in the schematic outline of the midbrain immunostained with the anti-tyrosine hydroxylase antibody (A). This inset in A includes fr, MT, hippocampus (Hip), and VTA. Scale bar = 1 mm for inset in A. Immunoblots of 5 or 20  $\mu$ g protein were probed with antibodies raised against AMPA receptor subunits (GluR1, GluR2/3, and GluR4) and NMDA receptor subunits (NR1, NR2A, and NR2B). Immunoreactivity for the presynaptic proteins synapsin I and synaptophysin, the neuronal marker NSE, the astrocyte marker GFAP, and ErbB1, was examined as well. Representative immunoblots are displayed. (B) Levels of immunoreactivity were measured by densitometry ( $n=5$ , each represents a pooled sample of two mice). Results are all normalized to protein levels in controls (100%) and plotted. \*  $P<0.05$ ,  $t$ -test.

the expression of the presynaptic proteins synapsin I and synaptophysin was not affected by EGF. Thus, EGF has no apparent influences on neurotransmitter release from afferent terminals in the VTA.

*In situ* hybridization reveals the expression of ErbB1 mRNA in rat midbrain (Seroogy et al., 1994; Kornblum et al., 1997). EGF circulating in peripheral blood can cross the blood–brain barrier (Pan and Kastin, 1999; Kastin et al., 1999) and activate ErbB1 in the brain (Futamura et al., 2003). In particular, the blood–brain barrier is leaky during early postnatal stage of rodents when the blood–brain barrier is not fully established (Tohmi et al., 2007). In agreement, biotinylated EGF efficiently penetrated the blood–brain barrier of neonatal mice and reached the mid-brain region. Peripherally administered EGF also triggered phosphorylation of ErbB1 as well as that of ErbB2 in the ventral midbrain tissue. It is possible that ErbB1 forms hetero-oligomers with ErbB2 in this brain region (Leahy, 2004) and phosphorylates ErbB2 (Fox and Kornblum, 2005; Gerecke et al., 2001). These results illustrate that circulating EGF must have significant impact on the mid-

brain dopaminergic system, at least, during early postnatal development.

Rodents treated with EGF as neonates exhibit schizophrenia-like behavioral abnormalities in prepulse inhibition, exploratory motor activity, and social interaction at the adult stages (Futamura et al., 2003; Tohmi et al., 2005; Sotoyama et al., 2007). These behavioral abnormalities induced by EGF may in part result from the alteration in the dopaminergic system (Sotoyama et al., 2007). Consistent with these observations, EGF-treated rats exhibits higher sensitivity to cocaine, which enhances glutamatergic neurotransmission to dopamine neurons (Ungless et al., 2001; Zhang et al., 1997; Mizuno et al., 2004). Cocaine facilitates AMPA receptor-mediated transmission in the VTA (Zhang et al., 1997; Ungless et al., 2001), enhances agonist-induced burst firing, and dopamine release in the nucleus accumbens, leading to behavioral and cognitive impairments (Tong et al., 1995; Giorgetti et al., 2001). The present findings suggest that neonatal EGF treatment may mimic the pharmacological action of cocaine.



The present synaptic effects of EGF on dopaminergic neurons appear not to be persistent, however. At P30, when 2 weeks passed after completion of EGF administration, there were no detectable influences remaining in the synaptic properties of dopaminergic neurons as well as in glutamate receptor expressions in the midbrain (H. Nawa, unpublished observations). In this context, further studies should determine how the change in the synaptic properties of dopaminergic neurons leads to the behavioral abnormalities at the adult stage.

**Acknowledgments**—This work was supported by the Basic Scientific Research (B), the Health and Labor Sciences Research Grants, a grant for Promotion of Niigata University Research Projects, and Core Research for Evolutional Science and Technology from the JST Corporation.

## REFERENCES

- Abe K, Xie FJ, Saito H (1991) Epidermal growth factor enhances short-term potentiation and facilitates induction of long-term potentiation in rat hippocampal slices. *Brain Res* 547:171–174.
- Abe K, Saito H (1992) Epidermal growth factor selectively enhances NMDA receptor-mediated increase of intracellular  $Ca^{2+}$  concentration in rat hippocampal neurons. *Brain Res* 587:102–108.
- Alexi T, Hefti F (1993) Trophic actions of transforming growth factor alpha on mesencephalic dopaminergic neurons developing in culture. *Neuroscience* 55:903–918.
- Birecree E, King LE Jr, Nanney LB (1991) Epidermal growth factor and its receptor in the developing human nervous system. *Dev Brain Res* 60:145–154.
- Blum M (1998) A null mutation in TGF- $\alpha$  leads to a reduction in midbrain dopaminergic neurons in the substantia nigra. *Nat Neurosci* 1:374–377.
- Bonci A, Malenka RC (1999) Properties and plasticity of excitatory synapses on dopaminergic and GABAergic cells in the ventral tegmental area. *J Neurosci* 19:3723–3730.
- Casper D, Blum M (1995) Epidermal growth factor and basic fibroblast growth factor protect dopaminergic neurons from glutamate toxicity in culture. *J Neurochem* 65:1016–1026.
- Casper D, Mytilineou C, Blum M (1991) EGF enhances the survival of dopamine neurons in rat embryonic mesencephalon primary cell culture. *J Neurosci Res* 30:372–381.
- Chen LW, Wei LC, Lang B, Ju G, Chan YS (2001) Differential expression of AMPA receptor subunits in dopamine neurons of the rat brain: a double immunocytochemical study. *Neuroscience* 106:149–160.
- Ferrari G, Toffano G, Skaper SD (1991) Epidermal growth factor exerts neurotrophic effects on dopaminergic and GABAergic CNS neurons: comparison with basic fibroblast growth factor. *J Neurosci Res* 30:493–497.
- Ford CP, Mark GP, Williams JT (2006) Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location. *J Neurosci* 26:2788–2797.
- Fox IJ, Kornblum HI (2005) Developmental profile of ErbB receptors in murine central nervous system: implications for functional interactions. *J Neurosci Res* 79:584–597.
- Fukunaga K, Horikawa K, Shibata S, Takeuchi Y, Miyamoto E (2002)  $Ca^{2+}$ /calmodulin-dependent protein kinase II-dependent long-term potentiation in the rat suprachiasmatic nucleus and its inhibition by melatonin. *J Neurosci Res* 70:799–807.
- Futamura T, Toyooka K, Iritani S, Nizato K, Nakamura R, Tsuchiya K, Someya T, Kakita A, Takahashi H, Nawa H (2002) Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients. *Mol Psychiatry* 7:673–682.
- Futamura T, Kakita A, Tohmi M, Sotoyama H, Takahashi H, Nawa H (2003) Neonatal perturbation of neurotrophic signaling results in abnormal sensorimotor gating and social interaction in adults: implication for epidermal growth factor in cognitive development. *Mol Psychiatry* 8:19–29.
- Geisler S, Derst C, Veh RW, Zahm DS (2007) Glutamatergic afferents of the ventral tegmental area in the rat. *J Neurosci* 27:5730–5743.
- Gerecke KM, Wyss JM, Karavanova I, Buonanno A, Carroll SL (2001) ErbB transmembrane tyrosine kinase receptors are differentially expressed throughout the adult rat central nervous system. *J Comp Neurol* 433:86–100.
- Giorgetti M, Hotsenpiller G, Ward P, Teppen T, Wolf ME (2001) Amphetamine-induced plasticity of AMPA receptors in the ventral tegmental area: effects on extracellular levels of dopamine and glutamate in freely moving rats. *J Neurosci* 21:6362–6369.
- Hatanaka H, Arimatsu Y (1984) Monoclonal antibodies to tyrosine hydroxylase from rat pheochromocytoma PC12h cells with special reference to nerve growth factor-mediated increase of the immunoprecipitable enzymes. *Neurosci Res* 1:253–263.
- Ikeda Y, Yahata N, Ito I, Nagano M, Toyota T, Yoshikawa T, Okubo Y, Suzuki H (2008) Low serum levels of brain-derived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia. *Schizophr Res* 101:58–66.
- Ishiyama J, Saito H, Abe K (1991) Epidermal growth factor and basic fibroblast growth factor promote the generation of long-term potentiation in the dentate gyrus of anaesthetized rats. *Neurosci Res* 12:403–411.
- Iwakura Y, Piao YS, Mizuno M, Takei N, Kakita A, Takahashi H, Nawa H (2005) Influences of dopaminergic lesion on epidermal growth factor-ErbB signals in Parkinson's disease and its model: neurotrophic implication in nigrostriatal neurons. *J Neurochem* 93:974–983.
- Johnson SW, North RA (1992) Two types of neurons in the rat ventral tegmental area and their synaptic inputs. *J Physiol* 450:455–468.
- Kastin AJ, Pan W, Maness LM, Banks WA (1999) Peptides crossing the blood-brain barrier: some unusual observations. *Brain Res* 848:96–100.
- Kim SO, Houtman JC, Jiang J, Ruppert JM, Bertics PJ, Frank SJ (1999) Growth hormone-induced alteration in ErbB-2 phosphorylation status in 3T3-F442a fibroblasts. *J Biol Chem* 274:36015–36024.
- Kornblum HI, Hussain RJ, Bronstein JM, Gall CM, Lee DC, Serogy KB (1997) Prenatal ontogeny of the epidermal growth factor receptor and its ligand, transforming growth factor alpha, in the rat brain. *J Comp Neurol* 380:243–261.
- Lazar LM, Blum M (1992) Regional distribution and developmental expression of epidermal growth factor and transforming growth factor- $\alpha$  mRNA in mouse brain by a quantitative nuclease protection assay. *J Neurosci* 12:1688–1697.
- Leahy DJ (2004) Structure and function of the epidermal growth factor (EGF/ErbB) family of receptors. *Adv Protein Chem* 68:1–27.
- Liang F, Hatanaka Y, Saito H, Yamamori T, Hashikawa T (2000) Differential expression of gamma-aminobutyric acid type B receptor-1a and -1b mRNA variants in GABA and non-GABAergic neurons of the rat brain. *J Comp Neurol* 416:475–495.
- Margolis EB, Lock H, Hjeltnad GO, Fields HL (2006) The ventral tegmental area revisited: is there an electrophysiological marker for dopaminergic neurons? *J Physiol* 577:907–924.
- Mizuno M, Malta RS Jr, Nagano T, Nawa H (2004) Conditioned place preference and locomotor sensitization after repeated administration of cocaine or methamphetamine in rats treated with epidermal growth factor during the neonatal period. *Ann N Y Acad Sci* 1025:612–618.
- Mizuno M, Sotoyama H, Narita E, Kawamura H, Namba H, Zheng Y, Eda T, Nawa H (2007) A cyclooxygenase-2 inhibitor ameliorates behavioral impairments induced by striatal administration of epidermal growth factor. *J Neurosci* 27:10116–10127.

- Nagano T, Namba H, Abe Y, Aoki H, Takei N, Nawa H (2007) In vivo administration of epidermal growth factor and its homologue attenuates developmental maturation of functional excitatory synapses in cortical GABAergic neurons. *Eur J Neurosci* 25:380–390.
- Neuhoff H, Neu A, Liss B, Roeper J (2002) Ih channels contribute to the different functional properties of identified dopaminergic subpopulations in the midbrain. *J Neurosci* 22:1290–1302.
- Nugent FS, Hwang AR, Udaka Y, Kauer JA (2008) High-frequency afferent stimulation induces long-term potentiation of field potentials in the ventral tegmental area. *Neuropsychopharmacology* 33:1704–1712.
- Obata K, Nishiye H, Fujita SC, Shirao T, Inoue H, Uchizono K (1986) Identification of a synaptic vesicle-specific 38,000-dalton protein by monoclonal antibodies. *Brain Res* 375:37–48.
- Pan W, Kastin AJ (1999) Entry of EGF into brain is rapid and saturable. *Peptides* 20:1091–1098.
- Paquet M, Tremblay M, Soghomonian JJ, Smith Y (1997) AMPA and NMDA glutamate receptor subunits in midbrain dopaminergic neurons in the squirrel monkey: an immunohistochemical and in situ hybridization study. *J Neurosci* 17:1377–1396.
- Patterson PH, Nawa H (1993) Neuronal differentiation factors/cytokines and synaptic plasticity. *Cell* 72(Suppl):123–137.
- Paxinos G, Franklin KBJ (2004) *The mouse brain in stereotaxic coordinates*, 2nd edition. San Diego: Academic Press.
- Pezzoli G, Zecchinelli A, Ricciardi S, Burke RE, Fahn S, Scarlato G, Careni A (1991) Intraventricular infusion of epidermal growth factor restores dopaminergic pathway in hemiparkinsonian rats. *Mov Disord* 6:281–287.
- Piao YS, Iwakura Y, Takei N, Nawa H (2005) Differential distributions of peptides in the epidermal growth factor family and phosphorylation of ErbB 1 receptor in adult rat brain. *Neurosci Lett* 390:21–24.
- Plata-Salaman CR (1991) Epidermal growth factor and the nervous system. *Peptides* 12:653–663.
- Schaudies RP, Christian EL, Savage CR Jr (1989) Epidermal growth factor immunoreactive material in the rat brain. Localization and identification of multiple species. *J Biol Chem* 264:10447–10450.
- Seroogy KB, Numan S, Gall CM, Lee DC, Kornblum HI (1994) Expression of EGF receptor mRNA in rat nigrostriatal system. *Neuroreport* 6:105–108.
- Sotoyama H, Namba H, Takei N, Nawa H (2007) Neonatal exposure to epidermal growth factor induces dopamine D2-like receptor super-sensitivity in adult sensorimotor gating. *Psychopharmacology (Berl)* 191:783–792.
- Tohmi M, Tsuda N, Mizuno M, Takei N, Frankland PW, Nawa H (2005) Distinct influences of neonatal epidermal growth factor challenge on adult neurobehavioral traits in four mouse strains. *Behav Genet* 35:615–629.
- Tohmi M, Tsuda N, Zheng Y, Mizuno M, Sotoyama H, Shibuya M, Kawamura M, Kakita A, Takahashi H, Nawa H (2007) The cellular and behavioral consequences of interleukin-1 alpha penetration through the blood-brain barrier of neonatal rats: a critical period for efficacy. *Neuroscience* 150:234–250.
- Tong ZY, Overton PG, Clark D (1995) Chronic administration of (+)-amphetamine alters the reactivity of midbrain dopaminergic neurons to prefrontal cortex stimulation in the rat. *Brain Res* 674:63–74.
- Ungless MA, Whistler JL, Malenka RC, Bonci A (2001) Single cocaine exposure in vivo induces long-term potentiation in dopamine neurons. *Nature* 411:583–587.
- Wanat MJ, Hopf FW, Stuber GD, Phillips PE, Bonci A (2008) Corticotropin-releasing factor increases mouse ventral tegmental area dopamine neuron firing through a protein kinase C-dependent enhancement of Ih. *J Physiol* 586:2157–2170.
- Watakabe A, Ohsawa S, Hashikawa T, Yamamori T (2006) Binding and complementary expression patterns of semaphorin 3E and plexin D1 in the mature neocortices of mice and monkeys. *J Comp Neurol* 499:258–273.
- White FJ (1996) Synaptic regulation of mesocorticolimbic dopamine neurons. *Annu Rev Neurosci* 19:405–436.
- Young ID, Allies L, Deugau K, Kisilevsky (1991) Transcription of cRNA for in situ hybridization from polymerase chain reaction-amplified DNA. *Lab Invest* 64:709–712.
- Yung KK (1998) Localization of ionotropic and metabotropic glutamate receptors in distinct neuronal elements of the rat substantia nigra. *Neurochem Int* 33:313–326.
- Zhang XF, Hu XT, White FJ, Wolf ME (1997) Increased responsiveness of ventral tegmental area dopamine neurons to glutamate after repeated administration of cocaine or amphetamine is transient and selectively involves AMPA receptors. *J Pharmacol Exp Ther* 281:699–706.
- Zheng Y, Sudou K, Nawa H, Namba H (2006) Field potential recording in the ventral tegmental area: pharmacological and toxicological evaluations of postsynaptic dopaminergic neuron activity. *Neurosci Res* 55:426–433.

(Accepted 31 October 2008)